High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate

British Journal of Haematology

Volumn 140, Issue 1, 2008, Pages 46-58

  Ingle, Gladys S ^a   Chan, Pamela ^a   Elliott, J Michael ^a   Chang, Wesley S ^b   Koeppen, Hartmut ^b   Stephan, Jean Philippe ^a   Scales, Suzie J ^a,b  

^a Department of Molecular Biology ^*  (United States)

^b GENENTECH INC   (United States)

Author keywords

Antibody therapy; CD19; CD21; CR2; Immunoconjugates; Non Hodgkin lymphoma

Indexed keywords

4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE [N' 2 DEACETYL N' 2 (3 MERCAPTO 1 OXOPROPYL)MAYTANSINE] CD19 ANTIBODY CONJUGATE; 4 (N MALEIMIDOMETHYL)CYCLOHEXANE 1 CARBOXYLATE [N' 2 DEACETYL N' 2 (3 MERCAPTO 1 OXOPROPYL)MAYTANSINE] CD21 ANTIBODY CONJUGATE; ANTIBODY CONJUGATE; CD19 ANTIBODY; CLATHRIN; COMPLEMENT COMPONENT C3D RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CONTROLLED STUDY; DAUDI CELL; DRUG CONJUGATION; DRUG RELEASE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RAJI CELL;

ANTIBODIES, NEOPLASM; ANTIGENS, CD19; APOPTOSIS; CELL LINE, TUMOR; CLATHRIN; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; LYMPHOMA, B-CELL; RECEPTORS, COMPLEMENT 3D;

EID: 36849080318     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06883.x     Document Type: Article

References (55)

1. American Cancer Society (2007). What is Non-Hodgkin's Lymphoma? In : Cancer Reference Information. Available at: http://www.cancer.org/downloads/STT/ CAFF2006PWSecured.pdf (accessed on June 2007).
2. Austin, C.D., De Maziere, A.M., Pisacane, P.I., van Dijk, S.M., Eigenbrot, C., Sliwkowski, M.X., Klumperman, J. Scheller, R.H. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Molecular Biology of the Cell, 15, 5268 5282.
3. Austin, C.D., Wen, X., Gazzard, L., Nelson, C., Scheller, R.H. Scales, S.J. (2005) Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proceedings of the National Academy of Sciences of the United States of America, 102, 17987 17992.
4. Barrault, D.V. Knight, A.M. (2004) Distinct sequences in the cytoplasmic domain of complement receptor 2 are involved in antigen internalization and presentation. Journal of Immunology, 172, 3509 3517.
5. Bonifacino, J.S. Traub, L.M. (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annual Review of Biochemistry, 72, 395 447.
6. Bradbury, L.E., Kansas, G.S., Levy, S., Evans, R.L. Tedder, T.F. (1992) The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. Journal of Immunology, 149, 2841 2850.
7. Chaouchi, N., Vazquez, A., Galanaud, P. Leprince, C. (1995) B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking. Journal of Immunology, 154, 3096 3104.
8. Cherukuri, A., Cheng, P.C. Pierce, S.K. (2001a) The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. Journal of Immunology, 167, 163 172.
9. Cherukuri, A., Cheng, P.C., Sohn, H.W. Pierce, S.K. (2001b) The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity, 14, 169 179.
10. Cohen, J.H., Fischer, E., Kazatchkine, M.D., Lenoir, G.M., Lefevre-Delvincourt, C. Revillard, J.P. (1987) Expression of CR1 and CR2 complement receptors following Epstein-Barr virus infection of Burkitt's lymphoma cell lines. Scandinavian Journal of Immunology, 25, 587 598.
11. Cvetkovic, R.S. Perry, C.M. (2006) Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. BioDrugs, 20, 253 257.
12. Doronina, S.O., Toki, B.E., Torgov, M.Y., Mendelsohn, B.A., Cerveny, C.G., Chace, D.F., DeBlanc, R.L., Gearing, R.P., Bovee, T.D., Siegall, C.B., Francisco, J.A., Wahl, A.F., Meyer, D.L. Senter, P.D. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnology, 21, 778 784.
13. Echeverri, C., Fisher, S., King, D. Craig, F.E. (2002) Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry. American Journal of Clinical Pathology, 117, 615 620.
14. Erickson, H.K., Park, P.U., Widdison, W.C., Kovtun, Y.V., Garrett, L.M., Hoffman, K., Lutz, R.J., Goldmacher, V.S. Blattler, W.A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Research, 66, 4426 4433.
15. Fearon, D.T. Carroll, M.C. (2000) Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annual Review of Immunology, 18, 393 422.
16. Flavell, D.J., Warnes, S.L., Bryson, C.J., Field, S.A., Noss, A.L., Packham, G. Flavell, S.U. (2006) The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. British Journal Haematology, 134, 157 170.
17. Fra, A.M., Williamson, E., Simons, K. Parton, R.G. (1994) Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. Journal of Biological Chemistry, 269, 30745 30748.
18. Freeman, C.B., Magrath, I.T., Benjamin, D., Makuch, R., Douglass, E.C. Santaella, M.L. (1982) Classification of cell lines derived from undifferentiated lymphomas according to their expression of complement and Epstein-Barr virus receptors: implications for the relationship between African and American Burkitt's lymphoma. Clinical Immunology and Immunopathology, 25, 103 113.
19. Fremeaux-Bacchi, V., Fischer, E., Lecoanet-Henchoz, S., Mani, J.C., Bonnefoy, J.Y. Kazatchkine, M.D. (1998) Soluble CD21 (sCD21) forms biologically active complexes with CD23: sCD21 is present in normal plasma as a complex with trimeric CD23 and inhibits soluble CD23-induced IgE synthesis by B cells. International Immunology, 10, 1459 1466.
20. Ghetie, M.A., Picker, L.J., Richardson, J.A., Tucker, K., Uhr, J.W. Vitetta, E.S. (1994) Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood, 83, 1329 1336.
21. Ghetie, M.A., Podar, E.M., Ilgen, A., Gordon, B.E., Uhr, J.W. Vitetta, E.S. (1997) Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 94, 7509 7514.
22. Gloghini, A. Carbone, A. (1993) The nonlymphoid microenvironment of reactive follicles and lymphomas of follicular origin as defined by immunohistology on paraffin-embedded tissues. Human Pathology, 24, 67 76.
23. Goulet, A.C., Goldmacher, V.S., Lambert, J.M., Baron, C., Roy, D.C. Kouassi, E. (1997) Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. Blood, 90, 2364 2375.
24. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.R., Upeslacis, J., Shochat, D., Mountain, A., Flowers, D.A. Bernstein, I. (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry, 13, 47 58.
25. James, J.S. Dubs, G. (1997) FDA approves new kind of lymphoma treatment. Food and Drug Administration. AIDS Treat News, 284, 2 3.
26. Khine, A.A., Firtel, M. Lingwood, C.A. (1998) CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. Journal of Cellular Physiology, 176, 281 292.
27. Kovtun, Y.V., Audette, C.A., Ye, Y., Xie, H., Ruberti, M.F., Phinney, S.J., Leece, B.A., Chittenden, T., Blattler, W.A. Goldmacher, V.S. (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Research, 66, 3214 3221.
28. Lopez-Matas, M., Rodriguez-Justo, M., Morilla, R., Catovsky, D. Matutes, E. (2000) Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia. Haematologica, 85, 1140 1145.
29. Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C. Kirchhausen, T. (2006) Dynasore, a cell-permeable inhibitor of dynamin. Developmental Cell, 10, 839 850.
30. Nadler, L.M., Ritz, J., Hardy, R., Pesando, J.M., Schlossman, S.F. Stashenko, P. (1981) A unique cell surface antigen identifying lymphoid malignancies of B cell origin. Journal of Clinical Investigation, 67, 134 140.
31. Nadler, L.M., Anderson, K.C., Marti, G., Bates, M., Park, E., Daley, J.F. Schlossman, S.F. (1983) B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. Journal of Immunology, 131, 244 250.
32. van Oosterhout, Y.V., van den Herik-Oudijk, I.E., Wessels, H.M., de Witte, T., van de Winkel, J.G. Preijers, F.W. (1994) Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Research, 54, 3527 3532.
33. Otsuka, M., Yakushijin, Y., Hamada, M., Hato, T., Yasukawa, M. Fujita, S. (2004) Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance. British Journal Haematology, 127, 416 424.
34. Perrin-Cocon, L.A., Villiers, C.L., Salamero, J., Gabert, F. Marche, P.N. (2004) B cell receptors and complement receptors target the antigen to distinct intracellular compartments. Journal of Immunology, 172, 3564 3572.
35. Petrie, R.J., Schnetkamp, P.P., Patel, K.D., Awasthi-Kalia, M. Deans, J.P. (2000) Transient translocation of the B cell receptor and Src homology 2 domain-containing inositol phosphatase to lipid rafts: evidence toward a role in calcium regulation. Journal of Immunology, 165, 1220 1227.
36. Polakis, P. (2005) Arming antibodies for cancer therapy. Current Opinion in Pharmacology, 5, 382 387.
37. Polson, A.G., Yu, S.F., Elkins, K., Zheng, B., Clark, S., Ingle, G.S., Slaga, D.S., Giere, L., Du, C., Tan, C., Hongo, J.A., Gogineni, A., Cole, M.J., Vandlen, R., Stephan, J.P., Young, J., Chang, W., Scales, S.J., Ross, S., Eaton, D. Ebens, A. (2007) Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin's lymphoma. Blood, 110, 616 623.
38. Press, O.W., Farr, A.G., Borroz, K.I., Anderson, S.K. Martin, P.J. (1989) Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Research, 49, 4906 4912.
39. Press, O.W., Howell-Clark, J., Anderson, S. Bernstein, I. (1994) Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood, 83, 1390 1397.
40. Pulczynski, S., Boesen, A.M. Jensen, O.M. (1993) Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood, 81, 1549 1557.
41. Pulczynski, S., Boesen, A.M. Jensen, O.M. (1994) Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells - an immunofluorescence and immunoelectron microscopy study. Leukemia Research, 18, 541 552.
42. Sapra, P. Allen, T.M. (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Research, 62, 7190 7194.
43. Schmid, S.L., McNiven, M.A. De Camilli, P. (1998) Dynamin and its partners: a progress report. Current Opinion in Cell Biology, 10, 504 512.
44. Scoazec, J.Y., Berger, F., Magaud, J.P., Brochier, J., Coiffier, B. Bryon, P.A. (1989) The dendritic reticulum cell pattern in B cell lymphomas of the small cleaved, mixed, and large cell types: an immunohistochemical study of 48 cases. Human Pathology, 20, 124 131.
45. Sieber, T., Schoeler, D., Ringel, F., Pascu, M. Schriever, F. (2003) Selective internalization of monoclonal antibodies by B-cell chronic lymphocytic leukaemia cells. British Journal Haematology, 121, 458 461.
46. Smith, M.R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22, 7359 7368.
47. Tedder, T.F., Goldmacher, V.S., Lambert, J.M. Schlossman, S.F. (1986) Epstein-Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. Journal of Immunology, 137, 1387 1391.
48. Tedder, T.F., Zhou, L.J. Engel, P. (1994) The CD19/CD21 signal transduction complex of B lymphocytes. Immunology Today, 15, 437 442.
49. Tessier, J., Cuvillier, A., Glaudet, F. Khamlichi, A.A. (2006). Internalization and molecular interactions of human CD21 receptor. Molecular Immunology, 44, 2415 2425.
50. Uckun, F.M., Jaszcz, W., Ambrus, J.L., Fauci, A.S., Gajl-Peczalska, K., Song, C.W., Wick, M.R., Myers, D.E., Waddick, K. Ledbetter, J.A. (1988) Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 71, 13 29.
51. Vervoordeldonk, S.F., Balkenende, A.Y., van den Berg, H., von dem Borne, A.E., van der Schoot, C.E., Van Leeuwen, E.F. Slaper-Cortenbach, I.C. (1996) Degradation of radioiodinated B cell monoclonal antibodies: inhibition via a FCgamma-receptor-II-mediated mechanism and by drugs. Cancer Immunology, Immunotherapy, 42, 24 30.
52. Vose, J.M. (1999) Antibody-targeted therapy for low-grade lymphoma. Seminars in Hematology, 36, 15 20.
53. Watts, C. Marsh, M. 1992). Endocytosis: what goes in and how? Journal of Cell Science 103 (Pt 1 1 8.
54. Wiels, J., Fellous, M. Tursz, T. (1981) Monoclonal antibody against a Burkitt lymphoma-associated antigen. Proceedings of the National Academy of Sciences of the United States of America, 78, 6485 6488.
55. Xie, H., Audette, C., Hoffee, M., Lambert, J.M. Blattler, W.A. (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. Journal of Pharmacology and Experimental Therapeutics, 308, 1073 1082.